1185. Risk Factors and Clinical Outcomes of Cancer Patients with Clostridium difficile Associated Diarrhea Co-infected with a Second Enteropathogen.
Session: Poster Abstract Session: Enteric Infections and Diagnostics
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • Yalamanchili 2017 ID Week Poster Final PDF.pdf (538.7 kB)
  • Background: Cancer patients are at an increased risk for C. difficile infection (CDI) which is often identified along with other enteropathogens. The impact of co-infections on outcomes has not been established in this population. We compared the risk factors and clinical characteristics of patients with CDI monoinfection (CDIM) and patients coinfected with bacterial (CDIB) or viral (CDIV) enteropathogens.

    Methods: Adult patients presenting with primary or recurrent CDI (n=88) identified on a two-step GI multiplex assay (Biofire) followed by toxin A/B EIA, were classified into CDIM (n=66), CDIB (n=12), and CDIV (n=10) groups. Demographic and clinical data were collected and risk factors and outcomes compared by Fisher’s exact test, ANOVA, and the Kruskal-Wallis test. CDI severity was determined using Zar’s criteria, presence of bacteremia, and ICU stay.

    Results: During the study period, 2,017 diarrheal samples were submitted to the microbiology laboratory. An enteric pathogen was identified in 311 (15%) patients. CDI was identified in 88 cases of which 22 (25%) had a second pathogen. CDIM was found in 66 (21%), CDIB in 12 (4%), and CDIV in 10 (3%) subjects. The most common co-pathogens identified were diarrheagenic E. coli in the CDIB group (9/12, 75%) and norovirus in the CDIV group (8/10, 80%). Groups were similar in terms of demographics, number of recurrences, health care acquisition, co-morbidities, disease severity, serum creatinine at presentation, presence of toxin by EIA, and mortality. Patients with CDIM were more likely to have a recent hospitalization than the CDIB group (44/66 67% vs. 3/12 25%, p=0.01). Clinical symptoms at presentation were similar for the three groups except for nausea which was more common in the CDIV group when compared to CDIM (8/10, 80% vs. 25/66, 38%; p=0.02). The use of proton pump inhibitors was similar in the three groups. There was however, a higher proportion of patients taking GABA-like drugs within 90 days among the CDIB patients (10/12, 83%) than the group with CDIM (26/66, 40%) p=0.01.

    Conclusion: In CDI cancer patients, co-infection with other enteropathogens is common. Patients with CDIB were less likely to have a recent admission to a health care facility. The use of GABA-like drugs was associated with a higher risk of bacterial co-infection.

    Harika Yalamanchili, DO1, Andrew Chao, MD2, Eduardo Yepez Guevara, MD3, Samuel L. Aitken, PharmD4, Micah Bhatti, MD, PhD5 and Pablo C. Okhuysen, MD, FACP, FIDSA4, (1)Infectious Disease, The University of Texas Health Science Center at Houston - MD Anderson Cancer Center, Houston, TX, (2)Infectious Disease, Baylor College of Medicine - MD Anderson Cancer Center, Houston, TX, (3)Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, (4)Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, (5)Pediatric Infectious Diseases, University of Chicago, Chicago, IL

    Disclosures:

    H. Yalamanchili, None

    A. Chao, None

    E. Yepez Guevara, None

    S. L. Aitken, None

    M. Bhatti, None

    P. C. Okhuysen, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.